Ozempic may slim your waistline, but without an accompanying exercise program, it is also quietly weakening your body.
An Unexpected Mechanism: Weight Loss Without Increased Exercise
When it comes to GLP-1 drugs — the class of obesity treatment medications booming in the United States — Vietnamese-American communities typically hear only about the benefits: the number on the scale goes down, the waistline shrinks, diabetes risk drops. Few mention what a new study just presented at the Endocrine Society conference (ENDO 2026) revealed: users of Ozempic, Wegovy, Mounjaro, and Zepbound are actually moving less after starting treatment, not more.
This is not mere observation. The research team analyzed Fitbit wearable device data from the National Institutes of Health's All of Us research program, tracking 753 obese adults using GLP-1 medication. Results showed that average daily steps declined from 5,047 to 4,487, while moderate to vigorous exercise time shortened from 28 minutes to 22 minutes per day.
While this decline may seem modest, accumulated over months it represents a concerning health trajectory — especially since these drugs not only burn fat but also reduce lean muscle mass, which is essential for strength, metabolism, and long-term mobility.
Why This Matters Especially for Vietnamese-American Healthcare Workers and Elderly
Within the Vietnamese-American community in the United States, two groups deserve particular attention: Vietnamese-American healthcare workers — who often self-prescribe or advise others about these medications — and early-generation refugee elders increasingly accessing GLP-1 through Medicare and Medicaid.
Vietnamese-American healthcare workers, particularly in densely populated communities like Little Saigon (Westminster, California), Houston (Texas), or suburban Washington D.C., often play a dual role: they are both potential patients and information providers for elderly parents or relatives with limited English proficiency. The findings from this study need to be communicated clearly in both directions.
For early-generation refugee elders — a group already prone to lower activity due to living conditions, joint pain, and lack of safe public spaces in many residential areas — the risk is even higher. The study found that the largest decreases in physical activity were recorded among men and people with a history of joint or muscle pain, two factors very common among elderly Vietnamese-Americans.
Medication Is Not a Complete Shortcut
The critical point many patients — and not a few prescribing doctors — may overlook: GLP-1 is not a standalone solution. Dr. Sajana Maharjan, the lead researcher from HSHS St. John's Hospital (Springfield, Illinois), emphasizes that exercise cannot be an "add if possible" factor but must be a mandatory component of the obesity treatment protocol using GLP-1 drugs. Without concurrent exercise intervention, the benefits of medication can be gradually eroded by the very muscle loss it causes.
This is why the question is not just "should I use Ozempic?" but also "who is monitoring the exercise regimen of the user?" In the American healthcare system, the answer is usually no one — unless the patient proactively asks.
Cost and Access Barriers — A Diaspora Perspective
One unavoidable reality: GLP-1 medications remain expensive and are not always fully covered by insurance. Many within the Vietnamese-American community — particularly small business owners without good group health insurance, or recent immigrants — must pay out of pocket or purchase through unofficial channels. When costs are high and expectations are great, the temptation to neglect exercise because the drug "handles everything" becomes harder to resist.
Meanwhile, the medication also carries side effects rarely discussed outside medical circles. The New York Post recently reported on certain unusual reactions recorded in Ozempic users — including auditory symptoms and strange sensations — showing that the side effect list continues to be expanded and monitored.
What Needs to Be Watched
The ENDO 2026 study is the first large-scale study using wearable device data to measure physical activity in GLP-1 users. The next step the medical community is awaiting is randomized controlled clinical trials to see whether specific exercise programs can prevent this decline in activity, and what intensity of exercise is sufficient to preserve muscle mass.
For the Vietnamese-American community, the practical step right now is: if you or a family member are using any GLP-1 medication, ask your doctor directly about daily step targets and an accompanying resistance training program. The drug is only one part of the equation.
Read the full original report from Science Daily at the source link below.